Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence

Yen Rung Chen, Dar Shih Hsieh, Chao Sheng Liao, Chyi Huey Bai, Chen Tau Su, Yeh You Shen, Jih Fang Hsieh, Alfred C. Liao, Chia Hung Kao

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The aim of this study was to evaluate the potential role of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with unexplained rising serum alpha-fetoprotein (AFP) levels after the treatment of hepatocellular carcinoma (HCC). Patients and Methods: Thirty-one FDG-PET studies were performed in 26 patients (age range, 45-83; 21 men and 5 women), who had undergone either surgical resection or interventional therapy for HCC, but were subsequently noted to have high AFP serum levels on routine follow-up examinations, although imaging studies and physical examinations were normal. The FDG-PET results were correlated with histological findings, as well as long-term radiological and clinical follow-up (shortest follow-up period after FDG-PET was 6 months). Results: FDG-PET was abnormal in 22 of the 31 studies (71.0%) among the 26 patients. Intrahepatic lesions were detected in 20 of a total 30 lesions (66.7%) in 18 studies of FDG-PET among 26 patients. Ten FDG-PET studies among 9 patients identified one intrahepatic lesion, while 3 studies among 3 patients identified more than one intrahepatic lesion. Extrahepatic metastases were found in 9/31 studies of FDG-PET (29.0%) among 8 patients. These metastatic foci, composed of increased FDG accumulation, were identified in several locations; lung (4 studies among 4 patients), bone (2 studies among 2 patients) and the peritoneum (4 studies among 3 patients). Overall, FDG-PET for detecting HCC recurrence demonstrated 22 true-positives, 8 false-negatives, 1 true-negative and 0 false-positive results. The sensitivity, specificity and accuracy of FDG-PET for detecting HCC recurrence was 73.3%, 100% and 74.2%, respectively. Conclusion: When conventional examinations are normal, FDG-PET is a valuable imaging tool in patients who have rising AFP levels after HCC treatment. FDG-PET whole-body scan also provides an important and valuable imaging study for detecting extrahepatic metastasis.

Original languageEnglish
Pages (from-to)4719-4725
Number of pages7
JournalAnticancer Research
Volume25
Issue number6 C
Publication statusPublished - Nov 2005
Externally publishedYes

Fingerprint

alpha-Fetoproteins
Positron-Emission Tomography
Hepatocellular Carcinoma
Recurrence
Serum
Neoplasm Metastasis
Whole Body Imaging
Peritoneum
Fluorodeoxyglucose F18
Physical Examination
Therapeutics

Keywords

  • F-fluorodeoxyglucose
  • Alpha-fetoprotein
  • Hepatocellular carcinoma
  • Positron emission tomography

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chen, Y. R., Hsieh, D. S., Liao, C. S., Bai, C. H., Su, C. T., Shen, Y. Y., ... Kao, C. H. (2005). Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Research, 25(6 C), 4719-4725.

Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. / Chen, Yen Rung; Hsieh, Dar Shih; Liao, Chao Sheng; Bai, Chyi Huey; Su, Chen Tau; Shen, Yeh You; Hsieh, Jih Fang; Liao, Alfred C.; Kao, Chia Hung.

In: Anticancer Research, Vol. 25, No. 6 C, 11.2005, p. 4719-4725.

Research output: Contribution to journalArticle

Chen, YR, Hsieh, DS, Liao, CS, Bai, CH, Su, CT, Shen, YY, Hsieh, JF, Liao, AC & Kao, CH 2005, 'Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence', Anticancer Research, vol. 25, no. 6 C, pp. 4719-4725.
Chen, Yen Rung ; Hsieh, Dar Shih ; Liao, Chao Sheng ; Bai, Chyi Huey ; Su, Chen Tau ; Shen, Yeh You ; Hsieh, Jih Fang ; Liao, Alfred C. ; Kao, Chia Hung. / Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. In: Anticancer Research. 2005 ; Vol. 25, No. 6 C. pp. 4719-4725.
@article{522da82f90fd40f68e981df9236329a2,
title = "Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence",
abstract = "The aim of this study was to evaluate the potential role of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with unexplained rising serum alpha-fetoprotein (AFP) levels after the treatment of hepatocellular carcinoma (HCC). Patients and Methods: Thirty-one FDG-PET studies were performed in 26 patients (age range, 45-83; 21 men and 5 women), who had undergone either surgical resection or interventional therapy for HCC, but were subsequently noted to have high AFP serum levels on routine follow-up examinations, although imaging studies and physical examinations were normal. The FDG-PET results were correlated with histological findings, as well as long-term radiological and clinical follow-up (shortest follow-up period after FDG-PET was 6 months). Results: FDG-PET was abnormal in 22 of the 31 studies (71.0{\%}) among the 26 patients. Intrahepatic lesions were detected in 20 of a total 30 lesions (66.7{\%}) in 18 studies of FDG-PET among 26 patients. Ten FDG-PET studies among 9 patients identified one intrahepatic lesion, while 3 studies among 3 patients identified more than one intrahepatic lesion. Extrahepatic metastases were found in 9/31 studies of FDG-PET (29.0{\%}) among 8 patients. These metastatic foci, composed of increased FDG accumulation, were identified in several locations; lung (4 studies among 4 patients), bone (2 studies among 2 patients) and the peritoneum (4 studies among 3 patients). Overall, FDG-PET for detecting HCC recurrence demonstrated 22 true-positives, 8 false-negatives, 1 true-negative and 0 false-positive results. The sensitivity, specificity and accuracy of FDG-PET for detecting HCC recurrence was 73.3{\%}, 100{\%} and 74.2{\%}, respectively. Conclusion: When conventional examinations are normal, FDG-PET is a valuable imaging tool in patients who have rising AFP levels after HCC treatment. FDG-PET whole-body scan also provides an important and valuable imaging study for detecting extrahepatic metastasis.",
keywords = "F-fluorodeoxyglucose, Alpha-fetoprotein, Hepatocellular carcinoma, Positron emission tomography",
author = "Chen, {Yen Rung} and Hsieh, {Dar Shih} and Liao, {Chao Sheng} and Bai, {Chyi Huey} and Su, {Chen Tau} and Shen, {Yeh You} and Hsieh, {Jih Fang} and Liao, {Alfred C.} and Kao, {Chia Hung}",
year = "2005",
month = "11",
language = "English",
volume = "25",
pages = "4719--4725",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 C",

}

TY - JOUR

T1 - Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence

AU - Chen, Yen Rung

AU - Hsieh, Dar Shih

AU - Liao, Chao Sheng

AU - Bai, Chyi Huey

AU - Su, Chen Tau

AU - Shen, Yeh You

AU - Hsieh, Jih Fang

AU - Liao, Alfred C.

AU - Kao, Chia Hung

PY - 2005/11

Y1 - 2005/11

N2 - The aim of this study was to evaluate the potential role of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with unexplained rising serum alpha-fetoprotein (AFP) levels after the treatment of hepatocellular carcinoma (HCC). Patients and Methods: Thirty-one FDG-PET studies were performed in 26 patients (age range, 45-83; 21 men and 5 women), who had undergone either surgical resection or interventional therapy for HCC, but were subsequently noted to have high AFP serum levels on routine follow-up examinations, although imaging studies and physical examinations were normal. The FDG-PET results were correlated with histological findings, as well as long-term radiological and clinical follow-up (shortest follow-up period after FDG-PET was 6 months). Results: FDG-PET was abnormal in 22 of the 31 studies (71.0%) among the 26 patients. Intrahepatic lesions were detected in 20 of a total 30 lesions (66.7%) in 18 studies of FDG-PET among 26 patients. Ten FDG-PET studies among 9 patients identified one intrahepatic lesion, while 3 studies among 3 patients identified more than one intrahepatic lesion. Extrahepatic metastases were found in 9/31 studies of FDG-PET (29.0%) among 8 patients. These metastatic foci, composed of increased FDG accumulation, were identified in several locations; lung (4 studies among 4 patients), bone (2 studies among 2 patients) and the peritoneum (4 studies among 3 patients). Overall, FDG-PET for detecting HCC recurrence demonstrated 22 true-positives, 8 false-negatives, 1 true-negative and 0 false-positive results. The sensitivity, specificity and accuracy of FDG-PET for detecting HCC recurrence was 73.3%, 100% and 74.2%, respectively. Conclusion: When conventional examinations are normal, FDG-PET is a valuable imaging tool in patients who have rising AFP levels after HCC treatment. FDG-PET whole-body scan also provides an important and valuable imaging study for detecting extrahepatic metastasis.

AB - The aim of this study was to evaluate the potential role of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with unexplained rising serum alpha-fetoprotein (AFP) levels after the treatment of hepatocellular carcinoma (HCC). Patients and Methods: Thirty-one FDG-PET studies were performed in 26 patients (age range, 45-83; 21 men and 5 women), who had undergone either surgical resection or interventional therapy for HCC, but were subsequently noted to have high AFP serum levels on routine follow-up examinations, although imaging studies and physical examinations were normal. The FDG-PET results were correlated with histological findings, as well as long-term radiological and clinical follow-up (shortest follow-up period after FDG-PET was 6 months). Results: FDG-PET was abnormal in 22 of the 31 studies (71.0%) among the 26 patients. Intrahepatic lesions were detected in 20 of a total 30 lesions (66.7%) in 18 studies of FDG-PET among 26 patients. Ten FDG-PET studies among 9 patients identified one intrahepatic lesion, while 3 studies among 3 patients identified more than one intrahepatic lesion. Extrahepatic metastases were found in 9/31 studies of FDG-PET (29.0%) among 8 patients. These metastatic foci, composed of increased FDG accumulation, were identified in several locations; lung (4 studies among 4 patients), bone (2 studies among 2 patients) and the peritoneum (4 studies among 3 patients). Overall, FDG-PET for detecting HCC recurrence demonstrated 22 true-positives, 8 false-negatives, 1 true-negative and 0 false-positive results. The sensitivity, specificity and accuracy of FDG-PET for detecting HCC recurrence was 73.3%, 100% and 74.2%, respectively. Conclusion: When conventional examinations are normal, FDG-PET is a valuable imaging tool in patients who have rising AFP levels after HCC treatment. FDG-PET whole-body scan also provides an important and valuable imaging study for detecting extrahepatic metastasis.

KW - F-fluorodeoxyglucose

KW - Alpha-fetoprotein

KW - Hepatocellular carcinoma

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=28444432614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444432614&partnerID=8YFLogxK

M3 - Article

C2 - 16334166

AN - SCOPUS:28444432614

VL - 25

SP - 4719

EP - 4725

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 C

ER -